DRUG REGISTRATION GUIDANCE DOCUMENT (DRGD) - BPFK

More documents

Recommendations

Info

Drug Registration Guidance Document (DRGD)NO.SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC)13. ANTIPSYCHOTIC AGENTS13.1 ALL ANTIPSYCHOTIC AGENTSThe following statement shall be included in the package inserts ofproducts containing antipsychotic:PREGNANCY AND LACTATIONNeonates exposed to antipsychotic drugs during the third trimester ofpregnancy are at risk for extrapyramidal and/or withdrawal symptomsfollowing delivery. There have been reports of agitation, hypertonia,hypotonia, tremor, somnolence, respiratory distress, and feeding disorderin these neonates. These complications have varied in severity; while insome cases symptoms have been self-limited, in other cases neonateshave required intensive care unit support and prolonged hospitalisation.[BRAND NAME] should be used during pregnancy only if the potentialbenefit justifies the potential risk to the foetus.Reference: Circular Bil (16) dlm BPFK/PPP/01/03 Jld 1: Direktif Kenyataan AmaranBerkaitan Dengan Risiko Extrapyrimidal And/or Withdrawal Symptoms Bagi NeonatYang Terdedah Kepada Produk Antipsikotik Semasa Trimester Ketiga Kehamilan PadaSisip Bungkusan Semua Produk Antipsikotik13.2 ATYPICAL ANTIPSYCHOTIC AGENTSThe following statement shall be included in the package inserts ofproducts containing atypical antipsychotic agents:a. Clozapineb. Olanzepinec. Risperidoned. Quetiapinee. Ziprasidonef. AripiprazoleWARNINGHyperglycemia and Diabetes MellitusHyperglycemia in some cases extreme and associated with ketoacidosisor hyperosmolar coma or death, has been reported in patients treatedwith atypical antipsychotics. Assessment of the relationship betweenatypical antipsychotics use and glucose abnormalities is complicated bythe possibility of an increased background risk of diabetes mellitus inpatients with schizophrenia and the increasing incidence of diabetesmellitus in the general population. Given this confounders, theNational Pharmaceutical Control Bureau (NPCB)First Edition, January 2013 Page | 362
Drug Registration Guidance Document (DRGD)NO.SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC)relationship between atypical antipsychotic use and hyperglycemiarelatedadverse events is not completely understood. However,epidemiological studies suggest an increased risk of treatment-emergenthyperglycemia-related adverse events in patients treated with the atypicalantipsychotics. Precise risk estimates for hyperglycemia-related adverseevents in patients treated with atypical antipsychotics are not available.Patients with an established diagnosis of diabetes mellitus who arestarted on atypical antipsychotics should be monitored regularly forworsening of glucose control. Patients with risk factors for diabetesmellitus (e.g. obesity, family history of diabetes) who are startingtreatment with atypical antipsychotics should undergo fasting bloodglucose testing at the beginning of treatment and periodically duringtreatment. Any patient treated with atypical antipsychotics should bemonitored for symptoms of hyperglycemia including polydipsia, polyuria,polyphagia, and weakness. Patients who develop symptoms ofhyperglycemia during treatment with atypical antipsychotics shouldundergo fasting blood glucose testing. In some cases, hyperglycemia hasresolved when the atypical antipsychotic was discontinued; however,some patients required continuation of anti-diabetic treatment despitediscontinuation of the suspect drug.Reference: Circular Bil (31)dlm BPFK/02/5/1.3: Tambahan Amaran Berkaitan DenganHyperglycemia Bagi Keluaran 'Atypical Antipsychotic Agents'14. APOMORPHINEPlease refer to DOPAMINERGIC INGREDIENT15. ARGININEThe following statement shall be included on the labels and in the packageinserts of oral preparations containing Arginine for health supplementproducts:WARNINGArginine is not recommended for patients following a heart attack.Reference: Circular Bil (64) dlm BPFK/02/5/1.3: Pernyataan Amaran Produk Mengandungi'Arginine'16. ARIPIPRAZOLEPlease refer to DOPAMINERGIC INGREDIENTNational Pharmaceutical Control Bureau (NPCB)First Edition, January 2013 Page | 363
Page 1 and 2:
Drug Registration Guidance Document
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Appearance/organoleptic(odor, color
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
ATTACHMENT 1Drug Registration Guida
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
PART IV: CLINICAL DOCUMENTSDrug Reg
Page 230 and 231:
ATTACHMENT 2Drug Registration Guida
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
APPENDIX 5:Drug Registration Guidan
Page 238 and 239:
1. GENERAL INFORMATIONSDrug Registr
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Route of AdministrationTAMC(CFU/g o
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
e) Example of label approved by the
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313: Drug Registration Guidance Document
Page 412 and 413:
Page 414 and 415:
Page 416 and 417:
Page 418 and 419:
Page 420 and 421:
Page 422 and 423:
Page 424 and 425:
Page 426 and 427:
Page 428 and 429:
Page 430 and 431:
Page 432 and 433:
Page 434 and 435:
Page 436 and 437:
Page 438 and 439:
Page 440 and 441:
Page 442 and 443:
Page 444 and 445:
Page 446 and 447:
Page 448 and 449:
Page 450 and 451:
Page 452 and 453:
Page 454 and 455:
Page 456 and 457:
Page 458 and 459:
Page 460 and 461:
Page 462 and 463:
Page 464 and 465:
Page 466 and 467:
Page 468 and 469:
Page 470 and 471:
Page 472 and 473:
Page 474 and 475:
Page 476 and 477:
Page 478 and 479:
Page 480 and 481:
Page 482 and 483:
Page 484 and 485:
Page 486 and 487:
Page 488 and 489:
Page 490 and 491:
Page 492 and 493:
Page 494 and 495:
Page 496 and 497:
Page 498 and 499:
Page 500:
show all

DRUG REGISTRATION GUIDANCE DOCUMENT (DRGD) - BPFK

Create successful ePaper yourself

Delete template?

Save as template?